CoChat
Sign Up
Cited by 466Nanoparticle-Based Drug DeliveryExtracellular vesicles in diseaseRNA Interference and Gene Delivery

Cell or Cell Membrane-Based Drug Delivery Systems

Open access
Tan, Songwei, Wu, Tingting, Zhang, Dan, Zhang, Zhiping·2015·Theranostics
DOI 10.7150/thno.11852PMC PMC4440443
Open this paper in CoChat — free accountOpen PDF

Abstract

Natural cells have been explored as drug carriers for a long period. They have received growing interest as a promising drug delivery system (DDS) until recently along with the development of biology and medical science. The synthetic materials, either organic or inorganic, are found to be with more or less immunogenicity and/or toxicity. The cells and extracellular vesicles (EVs), are endogenous and thought to be much safer and friendlier. Furthermore, in view of their host attributes, they may achieve different biological effects and/or targeting specificity, which can meet the needs of personalized medicine as the next generation of DDS. In this review, we summarized the recent progress in cell or cell membrane-based DDS and their fabrication processes, unique properties and applications, including the whole cells, EVs and cell membrane coated nanoparticles. We expect the continuing development of this cell or cell membrane-based DDS will promote their clinic applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.11852

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Red blood cells are exploited as delivery systems because they prolong drug life span in circulation and prevent immune clearance.

    “Red blood cells, or erythrocytes, have been exploited as delivery systems due to the advantages of prolonging the life span of drugs in circulation and preventing drugs from immune clearance for many years.”

    From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [195]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 138

  1. [1]Chertok B Webber MJ Succi MD Drug delivery interfaces in the 21st century: From science fiction ideas to viable technologies Mol Pharm 2013 10 3531 43 23915375 PMC3818793
  2. [2]Hubbell JA Langer R Translating materials design to the clinic Nat Mater 2013 12 963 6 24150414
  3. [3]Hu C-MJ Fang RH Luk BT Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies Nanoscale 2013 6 65 75 24280870
  4. [4]Wicki A Witzigmann D Balasubramanian V Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications J Control Release 2015 200 138 157 25545217
  5. [5]Tan SW Li X Guo Y Lipid-enveloped hybrid nanoparticles for drug delivery Nanoscale 2013 5 860 72 23292080
  6. [6]Bamrungsap S Zhao ZL Chen T Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system Nanomedicine 2012 7 1253 71 22931450
  7. [7]Al-Jamal WT Kostarelos K Liposomes: from aclinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine Acc Chem Res 2011 44 1094 104 21812415
  8. [8]Muthu MS Feng S-S Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success Expert Opin Drug Del 2013 10 151 5 23061654
  9. [9]Gao W Hu C-MJ Fang RH Liposome-like nanostructures for drug delivery J Mater Chem B 2013 1 6569 85 PMC3877745 24392221
  10. [10]Immordino ML Dosio F Cattel L Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int J Nanomed 2006 1 297 PMC2426795 17717971
  11. [12]Bangham AD Surrogate cells or Trojan horses. The discovery of liposomes BioEssays 1995 17 1081 8 8634070
  12. [13]van der Meel R Fens MHAM Vader P Extracellular vesicles as drug delivery systems: Lessons from the liposome field J Control Release 2014 195 72 85 25094032
  13. [15]Ding Q Chen J Wei X RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses Pharm Res 2013 30 60 9 22878683
  14. [16]Hamidi M Zarrin A Foroozesh M Applications of carrier erythrocytes in delivery of biopharmaceuticals J Control Release 2007 118 145 60 17270305
  15. [17]Sun D Zhuang X Zhang S Exosomes are endogenous nanoparticles that can deliver biological information between cells Adv Drug Delivery Rev 2013 65 342 7 22776312
  16. [18]van Dommelen SM Vader P Lakhal S Microvesicles and exosomes: Opportunities for cell-derived membrane vesicles in drug delivery J Control Release 2012 161 635 44 22138068
  17. [19]Yoo J-W Irvine DJ Discher DE Bio-inspired, bioengineered and biomimetic drug delivery carriers Nat Rev Drug Discov 2011 10 521 35 21720407
  18. [20]Choi D-S Kim D-K Kim Y-K Proteomics, transcriptomics and lipidomics of exosomes and ectosomes Proteomics 2013 13 1554 71 23401200
  19. [21]Witwer KW Buzás EI Bemis LT Standardization of sample collection, isolation and analysis methods in extracellular vesicle research J Extracellular Vesicles 2013 2 20360 PMC3760646 24009894
  20. [22]Millan CG Marinero MaLS Castaneda AZ Drug, enzyme and peptide delivery using erythrocytes as carriers J Control Release 2004 95 27 49 15013230
  21. [23]Hu C-MJ Fang RH Zhang L Erythrocyte-inspired delivery systems Adv Healthc Mater 2012 1 537 47 23184788
  22. [24]Stuckey DW Shah K Stem cell-based therapies for cancer treatment: separating hope from hype Nat Rev Cancer 2014 14 683 91 25176333 PMC4234304
  23. [25]Tang K Zhang Y Zhang H Delivery of chemotherapeutic drugs in tumour cell-derived microparticles Nat Commun 2012 3 1282 23250412
  24. [26]Toledano Furman NE Lupu-Haber Y Bronshtein T Reconstructed stem cell nanoghosts: A natural tumor targeting platform Nano Lett 2013 13 3248 55 23786263
  25. [27]Hu C-MJ Zhang L Aryal S Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform Proc Natl Acad Sci USA 2011 108 10980 5 21690347 PMC3131364
  26. [28]Luk BT Hu C-MJ Fang RH Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles Nanoscale 2014 6 2730 7 24463706 PMC3954976
  27. [29]Aryal S Hu C-MJ Fang RH Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release Nanomedicine 2013 8 1271 80 23409747
  28. [30]Gao W Hu C-MJ Fang RH Surface functionalization of gold nanoparticles with red blood cell membranes Adv Mater 2013 25 3549 53 23712782 PMC4138311
  29. [31]Hu C-MJ Fang RH Copp J A biomimetic nanosponge that absorbs pore-forming toxins Nat Nanotechnol 2013 8 336 40 23584215 PMC3648601
  30. [32]Hu C-MJ Fang RH Luk BT Nanoparticle-detained toxins for safe and effective vaccination Nat Nanotechnol 2013 8 933 8 24292514 PMC3878426
  31. [33]Copp JA Fang RH Luk BT Clearance of pathological antibodies using biomimetic nanoparticles Proc Natl Acad Sci USA 2014 111 13481 6 25197051 PMC4169917
  32. [34]Fang RH Hu C-MJ Luk BT Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery Nano Lett 2014 14 2181 8 24673373 PMC3985711
  33. [36]Batrakova EV Gendelman HE Kabanov AV Cell-mediated drug delivery Expert Opin Drug Del 2011 8 415 33 PMC3062753 21348773
  34. [37]Godfrin Y Horand F Franco R International seminar on the red blood cells as vehicles for drugs Expert Opin Biol Ther 2012 12 127 33 22023703 PMC3492745
  35. [38]Kolesnikova TA Skirtach AG Möhwald H Red blood cells and polyelectrolyte multilayer capsules: natural carriers versus polymer-based drug delivery vehicles Expert Opin Drug Del 2013 10 47 58 23078091
  36. [39]Tsong TY Electroporation of cell membranes Biophys J 1991 60 297 306 1912274 PMC1260065
  37. [40]Lizano C Sanz S Luque J In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure Biochimica et Biophysica Acta-General Subjects 1998 1425 328 36 9795248
  38. [41]Phua KK Boczkowski D Dannull J Whole blood cells loaded with messenger RNA as an anti-tumor vaccine Adv Healthc Mater 2013 837 42 24339387 PMC4053491
  39. [42]Dong Q Jin W Monitoring diclofenac sodium in single human erythrocytes introduced by electroporation using capillary zone electrophoresis with electrochemical detection Electrophoresis 2001 22 2786 92 11545409
  40. [43]He H Ye J Wang Y Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application J Control Release 2013 176 123 32 24374002 PMC3939723
  41. [44]Biagiotti S Paoletti MF Fraternale A Drug delivery by red blood cells IUBMB Life 2011 63 621 31 21766411
  42. [45]Ahn S Jung SY Seo E Gold nanoparticle-incorporated human red blood cells (RBCs) for X-ray dynamic imaging Biomaterials 2011 32 7191 9 21777977
  43. [46]Antonelli A Sfara C Manuali E Encapsulation of superparamagnetic nanoparticles into red blood cells as new carriers of MRI contrast agents Nanomedicine 2011 6 211 23 21385124
  44. [47]Ferrauto G Delli Castelli D Di Gregorio E Lanthanide-loaded erythrocytes as highly sensitive Chemical Exchange Saturation Transfer (CEST) MRI contrast agents J Am Chem Soc 2013 136 638 41 24359116
  45. [48]Wang C Sun X Cheng L Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer Adv Mater 2014 26 4794 802 24838472
  46. [49]Flower R Peiretti E Magnani M Observation of erythrocyte dynamics in the retinal capillaries and choriocapillaris using ICG-loaded erythrocyte ghost cells Invest Ophth Vis Sci 2008 49 5510 6 18708621
  47. [50]Anselmo AC Gupta V Zern BJ Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells ACS nano 2013 7 11129 37 24182189 PMC4128963
  48. [51]Chambers E Mitragotri S Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes J Control Release 2004 100 111 9 15491815
  49. [52]Chambers E Mitragotri S Long circulating nanoparticles via adhesion on red blood cells: mechanism and extended circulation Exp Biol Med 2007 232 958 66 17609513
  50. [53]Mai TD d'Orlye F Menager C Red blood cells decorated with functionalized core-shell magnetic nanoparticles: elucidation of the adsorption mechanism Chem Commun 2013 49 5393 5 23652340
  51. [54]Shi G Mukthavaram R Kesari S Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo Adv Healthc Mater 2014 3 142 8 23798381 PMC3956753
  52. [55]Mukthavaram R Shi G Kesari S Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes J Control Release 2014 183 146 53 24685706 PMC4683104
  53. [56]Magnani M Chiarantini L Mancini U Preparation and characterization of biotinylated red blood cells Biotechnol Appl Biochem 1994 20 335 45 7818803
  54. [57]Taylor RP Sutherland WM Reist CJ Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment Proc Natl Acad Sci USA 1991 88 3305 9 1826564 PMC51435
  55. [58]Kontos S Kourtis IC Dane KY Engineering antigens for in situ erythrocyte binding induces T-cell deletion Proc Natl Acad Sci USA 2013 110 E60 E8 23248266 PMC3538192
  56. [59]Corinti S Chiarantini L Dominici S Erythrocytes deliver Tat to interferon-γ-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro J Leukocyte Biol 2002 71 652 8 11927652
  57. [60]Shi J Kundrat L Pishesha N Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes Proc Natl Acad Sci USA 2014 111 10131 6 24982154 PMC4104923
  58. [61]Hamidi M Tajerzadeh H Dehpour A-R In vitro characterization of human intact erythrocytes loaded by enalaprilat Drug Deliv 2001 8 223 30 11757780
  59. [63]Perno C-F Santoro N Balestra E Red blood cells mediated delivery of 9-(2-phosphonylmethoxyethyl) adenine to primary macrophages: efficiency, metabolism and activity against human immunodeficiency virus or herpes simplex virus Antivir Res 1997 33 153 64 9037372
  60. [64]Fraternale A Casabianca A Orlandi C Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model Antivir Res 2002 56 263 72 12406509
  61. [66]Ihler GM Glew RH Schnure FW Enzyme loading of erythrocytes Proc Natl Acad Sci USA 1973 70 2663 6 4354859 PMC427078
  62. [67]Ritter SC Milanick MA Meissner KE Encapsulation of FITC to monitor extracellular pH: a step towards the development of red blood cells as circulating blood analyte biosensors Biomed Opt Express 2011 2 2012 21 21750776 PMC3130585
  63. [68]Picas L Rico F Deforet M Structural and mechanical heterogeneity of the erythrocyte membrane reveals hallmarks of membrane stability ACS nano 2013 7 1054 63 23347043
  64. [69]Gutiérrez Millán C Castañeda AZ Sayalero Marinero ML Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis Blood Cells Mol Dis 2004 33 132 40 15315791
  65. [70]Jordán JA Alvarez FJ Lotero LA In vitro phagocytosis of carrier mouse red blood cells is increased by Band 3 cross-linking or diamide treatment Biotechnol Appl Biochem 2001 34 143 9 11730481
  66. [71]Jordán JA Alvarez FJ Lotero LA In vivo behaviour of rat band 3 cross-linked carrier erythrocytes Biochimie 1998 80 325 32 9672753
  67. [72]Eichler H Gasic S Bauer K In vivo clearance of antibody-sensitized human drug carrier erythrocytes Clin Pharmacol Ther 1986 40 300 3 3091309
  68. [73]Delcea M Sternberg N Yashchenok AM Nanoplasmonics for dual-molecule release through nanopores in the membrane of red blood cells ACS nano 2012 6 4169 80 22463598
  69. [74]Ing R Segura M Thawani N Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation J Immunol 2006 176 441 50 16365437
  70. [75]Cremel M Guérin N Horand F Red blood cells as innovative antigen carrier to induce specific immune tolerance Int J Pharma 2013 443 39 49 23305866
  71. [76]Hu Y-L Huang B Zhang T-Y Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection Mol Pharm 2012 9 2698 709 22862421
  72. [77]Sasportas LS Kasmieh R Wakimoto H Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy Proc Natl Acad Sci USA 2009 106 4822 7 19264968 PMC2660771
  73. [78]Ito S Natsume A Shimato S Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma Cancer Gene Ther 2010 17 299 306 19893595
  74. [79]Dembinski JL Wilson SM Spaeth EL Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer Cytotherapy 2013 15 20 32 23260083 PMC3709838
  75. [80]Seo SH Kim KS Park SH The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity Gene Ther 2011 18 488 95 21228885 PMC3125103
  76. [81]Ryu CH Park SH Park SA Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells Hum Gene Ther 2011 22 733 43 21261460
  77. [82]Xu G Jiang X-D Xu Y Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats Cell Biol Int 2009 33 466 74 18725309
  78. [83]Li L Guan Y Liu H Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy ACS nano 2011 5 7462 70 21854047
  79. [84]Mooney R Weng YM Garcia E Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy J Control Release 2014 191 82 9 24952368 PMC4156897
  80. [85]Cao BR Yang MY Zhu Y Stem cells loaded with nanoparticles as a drug carrier for in vivo breast cancer therapy Adv Mater 2014 26 4627 31 24890678 PMC4292873
  81. [86]Schnarr K Mooney R Weng YM Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer Adv Healthc Mater 2013 2 976 82 23592703
  82. [87]Mooney R Roma L Zhao DH Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy ACS Nano 2014 8 12450 60 25375246 PMC4278682
  83. [88]Huang X Zhang F Wang H Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery Biomaterials 2013 34 1772 80 23228423 PMC3538138
  84. [89]Mooney R Weng Y Tirughana-Sambandan R Neural stem cells improve intracranial nanoparticle retention and tumor-selective distribution Future Oncology 2014 10 401 15 24559447 PMC5624796
  85. [90]Ljujic B Milovanovic M Volarevic V Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice Scientific Reports 2013 3 2298 23892388 PMC3725512
  86. [91]Karnoub AE Dash AB Vo AP Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 2007 449 557 63 17914389
  87. [92]Rosland GV Svendsen A Torsvik A Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation Cancer Res 2009 69 5331 9 19509230
  88. [93]Murdoch C Giannoudis A Lewis CE Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood 2004 104 2224 34 15231578
  89. [94]Wang HY Chen L Tumor microenviroment and hepatocellular carcinoma metastasis J Gastroen Hepatol 2013 28 43 8 23855295
  90. [95]Watanabe MAE Oda JMM Amarante MK Regulatory T cells and breast cancer: implications for immunopathogenesis Cancer Metast Rev 2010 29 569 79 20830504
  91. [96]Moon JJ Huang B Irvine DJ Engineering nano- and microparticles to tune immunity Adv Mater 2012 24 3724 46 22641380 PMC3786137
  92. [97]Vinogradov S Warren G Wei X Macrophages associated with tumors as potential targets and therapeutic intermediates Nanomedicine 2014 9 695 707 24827844 PMC4149280
  93. [98]Akao Y Iio A Itoh T Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages Mol Ther 2011 19 395 9 21102562 PMC3034851
  94. [99]Tao YH Ning MM Dou HY A novel therapeutic system for malignant glioma: nanoformulation, pharmacokinetic, and anticancer properties of cell-nano-drug delivery Nanomed-Nanotechnol 2013 9 222 32 23123732
  95. [100]Choi MR Stanton-Maxey KJ Stanley JK A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors Nano Lett 2007 7 3759 65 17979310
  96. [101]Keliher EJ Yoo J Nahrendorf M 89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging Bioconjugate Chem 2011 22 2383 9 PMC3244512 22035047
  97. [102]Alizadeh D Zhang LY Hwang J Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas Nanomed-Nanotechnol 2010 6 382 90 PMC2866635 19836468
  98. [103]He CB Hu YP Yin LC Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 2010 31 3657 66 20138662
  99. [105]Van Lint S Goyvaerts C Maenhout S Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy Cancer Res 2012 72 1661 71 22337996
  100. [106]Sheikh NA Petrylak D Kantoff PW Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer Cancer Immunol Immun 2013 62 137 47 PMC3541926 22865266
  101. [107]Théry C Ostrowski M Segura E Membrane vesicles as conveyors of immune responses Nat Rev Immunol 2009 9 581 93 19498381
  102. [108]Tan A De La Pena H Seifalian AM The application of exosomes as a nanoscale cancer vaccine Int J Nanomed 2010 5 889 900 PMC2990382 21116329
  103. [109]Zhuang XY Xiang XY Grizzle W Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain Mol Ther 2011 19 1769 79 21915101 PMC3188748
  104. [110]Sun D Zhuang X Xiang X A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes Mol Ther 2010 18 1606 14 20571541 PMC2956928
  105. [111]Al-Nedawi K Meehan B Kerbel RS Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR Proc Natl Acad Sci USA 2009 106 3794 9 19234131 PMC2656159
  106. [112]Bahmani B Bacon D Anvari B Erythrocyte-derived photo-theranostic agents: hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications Sci Rep-UK 2013 3 2180 PMC3709166 23846447
  107. [113]Gupta N Patel B Ahsan F Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: Preparation and characterization Pharm Res 2014 31 1553 65 24449438 PMC5322565
  108. [114]Tian X Zhu M Tian Y A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma Biomaterials 2012 33 6147 54 22681975
  109. [115]Li JH Liu KC Liu Y Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity Nat Immunol 2013 14 793 803 23832071
  110. [116]Bosman G Werre J Willekens F Erythrocyte ageing in vivo and in vitro: structural aspects and implications for transfusion Transfusion Med 2008 18 335 47 19140816
  111. [117]Rho J Chung J Im H Magnetic nanosensor for detection and profiling of erythrocyte-derived microvesicles ACS nano 2013 7 11227 33 24295203 PMC3898036
  112. [118]Chang M Hsiao J-K Yao M Homologous RBC-derived vesicles as ultrasmall carriers of iron oxide for magnetic resonance imaging of stem cells Nanotechnology 2010 21 235103 20479509
  113. [119]Pascucci L Coccè V Bonomi A Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery J Control Release 2014 192 262 70 25084218
  114. [120]Silva AKA Di Corato R Pellegrino T Cell-derived vesicles as a bioplatform for the encapsulation of theranostic nanomaterials Nanoscale 2013 5 11374 84 23827988
  115. [121]Gaillard ME Bottero D Errea A Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes Vaccine 2014 32 931 7 24397896
  116. [122]Bottero D Gaillard M Errea A Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection Vaccine 2013 31 5262 8 24012570
  117. [123]Gujrati V Kim S Kim S-H Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy ACS nano 2014 8 1525 37 24410085
  118. [124]Wolfers J Lozier A Raposo G Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming Nat Med 2001 7 297 303 11231627
  119. [125]Simpson RJ Jensen SS Lim JWE Proteomic profiling of exosomes: Current perspectives Proteomics 2008 8 4083 99 18780348
  120. [126]Zeelenberg IS Ostrowski M Krumeich S Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses Cancer Res 2008 68 1228 35 18281500
  121. [127]Paulis LE Mandal S Kreutz M Dendritic cell-based nanovaccines for cancer immunotherapy Curr Opin Immunol 2013 25 389 95 23571027
  122. [128]Lakhal S Wood MJ Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers BioEssays 2011 33 737 41 21932222
  123. [129]Nanjundappa RH Wang R Xie Y GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses Vaccine 2011 29 3538 47 21406265
  124. [130]Escudier B Dorval T Chaput N Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial J Transl Med 2005 3 10 15740633 PMC554765
  125. [131]Morse MA Garst J Osada T A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer J Transl Med 2005 3 9 15723705 PMC551593
  126. [132]Tian Y Li S Song J A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy Biomaterials 2014 35 2383 90 24345736
  127. [133]Skog J Würdinger T van Rijn S Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat Cell Biol 2008 10 1470 6 19011622 PMC3423894
  128. [134]Alvarez-Erviti L Seow Y Yin H Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nature biotechnology 2011 29 341 5 21423189
  129. [135]Ohno S-i Takanashi M Sudo K Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells Mol Ther 2012 21 185 91 23032975 PMC3538304
  130. [137]Jang SC Kim OY Yoon CM Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors ACS nano 2013 7 7698 710 24004438
  131. [138]Jo W Kim J Yoon J Large-scale generation of cell-derived nanovesicles Nanoscale 2014 6 12056 64 25189198
  132. [139]Jo W Jeong D Kim J Microfluidic fabrication of cell-derived nanovesicles as endogenous RNA carriers Lab Chip 2014 14 1261 9 24493004
  133. [140]Piao J-G Wang L Gao F Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy ACS nano 2014 8 10414 25 25286086
  134. [141]Cheng H Fan Z Zhou H Structural elucidation of cell membrane-derived nanoparticles using molecular probes J Mater Chem B 2014 2 8231 8 32262097
  135. [142]Hu C-MJ Fang RH Luk BT 'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach Nanoscale 2013 5 2664 8 23462967 PMC3667603
  136. [143]Fang RH Hu C-MJ Chen KNH Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles Nanoscale 2013 5 8884 8 23907698 PMC3831007
  137. [144]Li L-L Xu J-H Qi G-B Core-shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery ACS nano 2014 8 4975 83 24716550
  138. [145]Parodi A Quattrocchi N van de Ven AL Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions Nat Nanotechnol 2013 8 61 8 23241654 PMC3751189

Cited by

Sorted by citations

Authors
Tan, S., Wu, T., Zhang, D., & Zhang, Z.
Affiliations
  • Huazhong University of Science and Technology (CN)
  • Tongji University (CN)
Corresponding author
Zhang, Zhiping
ORCID
Venue
Theranostics
Publisher
Ivyspring International Publisher
Published
2015
Volume
5
Issue
8
Pages
863-881
ISSN
1838-7640 (ISSN-L)
DOI
10.7150/thno.11852
PMC
PMC4440443
OpenAlex
W2114235650
Cited by
466
References
3
Citations by year
2026: 11 · 2025: 44 · 2024: 51 · 2023: 51 · 2022: 56 · 2021: 54 · 2020: 58 · 2019: 44 · 2018: 45 · 2017: 27 · 2016: 23 · 2015: 2
FWCI
1.95
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Theranostics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • China Postdoctoral Science Foundation (2013T60722)
  • National Key Research and Development Program of China (2012CB932501)
  • Fundamental Research Funds for the Central Universities (2014QN134, 2014TS091)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
cell-based drug delivery, extracellular vesicles, cell membrane-coated nanoparticles, targeted drug delivery, personalized medicine, immunogenicity
MeSH terms
Cell Membrane, Cells, Drug Carriers, Humans, Drug Delivery Systems, Drug Discovery, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review